Skip to main content

Caliper Reports Q2 Revenue Gains

NEW YORK, Aug. 5 (GenomeWeb News) - Caliper Life Sciences today reported a 222 percent gain in second-quarter revenues, driven by sales from Zymark, which the firm acquired in July 2003.

 

Caliper had revenues of $18.9 million in the quarter, up from $5.9 million in the second quarter of 2003.

 

The Hopkinton, Mass.-based firm posted a net loss of $9.5 million, or $.33 per share, compared to a net loss of $9.5 million, or $.38 per share, in the comparable period last year. This year's second-quarter results include a $2.4 million restructuring charge related to future lease costs of facilities no longer occupied following consolidation of its Mountain View, Calif., operations. The results also included $180,000 in severance charges and related benefits incurred in connection with the elimination of 14 positions.

 

Caliper finished the quarter with $52.9 million in cash, equivalents and short-term marketable securities.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.